Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

Yokota Shumpei; Itoh Yasuhiko; Morio Tomohiro; Origasa Hideki; Sumitomo Naokata; Tomobe Minako; Tanaka Kunihiko; Minota Seiji

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

【24h】

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

机译：在现实世界中，Tocilizumab在系统性幼年特发性关节炎中的应用：日本417位患者上市后监测随访1年的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives To evaluate the safety and effectiveness of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) in real-world clinical settings in Japan.

机译：目的在日本的实际临床环境中评估托珠单抗（TCZ）在系统性幼年特发性关节炎（sJIA）患者中的安全性和有效性。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2016年第9期|共7页
作者
Yokota Shumpei; Itoh Yasuhiko; Morio Tomohiro; Origasa Hideki; Sumitomo Naokata; Tomobe Minako; Tanaka Kunihiko; Minota Seiji;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
Juvenile Idiopathic Arthritis; DMARDs (biologic); Treatment;

机译：幼年特发性关节炎;DMARDs（生物）;治疗;
入库时间 2022-08-18 10:16:36

相似文献

外文文献
中文文献
专利

1. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan [J] . Yokota Shumpei, Itoh Yasuhiko, Morio Tomohiro, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第9期

机译：在现实世界中，Tocilizumab在系统性幼年特发性关节炎中的应用：日本417位患者上市后监测随访1年的结果
2. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial [J] . Navita L. Mallalieu, Sunethra Wimalasundera, Joy C. Hsu, Pediatric rheumatology online journal . 2019,第1期

机译：静脉给药于患有两年大于两年龄的患者，具有全身性幼年特发性关节炎：开放标签临床试验结果
3. Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan [J] . Yamamoto Kazuhiko, Goto Hajime, Hirao Kenzo, The Journal of rheumatology . 2015,第8期

机译：Tocilizumab的长期安全性：日本5573名类风湿关节炎患者上市后三年随访的结果
4. Biomarker Status of Proteins in Circulating Immune Complexes Isolated from Dermatomyositis, Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis Plasma [C] . Leticia Cano American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：循环免疫复合物中蛋白质的生物标志物状态从皮肤病，全身性狼疮红斑和幼年特发性关节炎等离子体中分离出来的免疫复合物
5. The Use of S100 Proteins Testing in Juvenile Idiopathic Arthritis and Autoinflammatory Diseases in a Pediatric Clinical Setting: A Retrospective Analysis [D] . Aljaberi, Najla. 2020

机译：在儿科临床环境中使用S100蛋白在幼年作用关节炎和自身炎症疾病中的使用：回顾性分析
6. Extended report: Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan [O] . Shumpei Yokota, Yasuhiko Itoh, Tomohiro Morio, -1

机译：扩展报告：在现实世界中Tocilizumab在系统性幼年特发性关节炎中的临床应用：来自日本417名患者的上市后监测随访1年的结果
7. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial [O] . F. De Benedetti, N. Ruperto, G. Espada, 2014

机译：Sysic幼年特发性关节炎的对照治疗期间追赶增长：来自第3期临床试验的2年数据

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

摘要

著录项

相似文献

相关主题

期刊订阅